Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Paulsen Pharma Consulting AB
AB
Active
Org 5568966146
Kristinebergs Slottsväg 7
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2012
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 0
EBITDA margin
—
-114% vs 2024
Equity ratio
63.9%
Financial strength
Net profit 2025
SEK 689K
+68% vs 2024
EBITDA — year on year
SEK millions
1M
1M
1M
0M
0M
1M
2021
0M
-100%
2022
0M
0%
2023
1M
+100%
2024
0M
-100%
2025
Key figures
Annual report 2025
Revenue
SEK 0
—
EBITDA
SEK -72K
-114%
Net profit
SEK 689K
+68%
Total assets
SEK 3,6M
+23%
Equity
SEK 2,3M
+27%
Employees
0
—
Company information
Legal name
Paulsen Pharma Consulting AB
Org number
5568966146
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 juni 2012
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Farmaceutisk regulatorisk konsultverksamhet inom kemi- farmaciområdet
Contact
Address
Kristinebergs Slottsväg 7
Phone
+46733542142
Email
ulla.paulsen@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Stockholm
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
1M
2021
0M
2022
1M
2023
1M
2024
0M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
1M
2021
0M
2022
0M
2023
1M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
878
458
542
631
0
Staff expenses
—
—
—
—
—
EBITDA
807
386
463
529
−72
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
807
386
463
529
−72
Net financials
−1
12
18
41
1 102
Profit before tax
666
366
451
523
875
Tax
−144
−78
−98
−114
−186
Net profit
522
288
353
409
689
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
2 436
2 399
2 628
2 932
3 594
Equity
1 329
1 432
1 597
1 811
2 297
Long-term debt
0
0
0
0
0
Short-term debt
298
124
157
201
222
Total debt
298
124
157
201
222
Financial ratios
5-year trend
EBITDA margin
-7200000.0%
This company
15.8%
Market median
-45569720% vs market
2021
2025
Equity ratio
63.9%
This company
38.2%
Market median
+67% vs market
2021
2025
Return on equity
30.0%
This company
18.4%
Market median
+63% vs market
2021
2025
Net profit margin
68900000.0%
This company
8.1%
Market median
+850617184% vs market
2021
2025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2021
2025
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
EL
Eva Linnea Karolina Sörman
Deputy Board Member
2022
UB
Ulla Birgit Paulsen
Board of Directors
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Paulsen Pharma Consulting AB also hold positions in
0
other companies.
Person
Role here
Other companies
Eva Linnea Karolina Sörman
Deputy Board Member
0 companies
Ulla Birgit Paulsen
Board of Directors
0 companies